...Sandra Domingo; Cristina Solé; Teresa Moliné; Berta Ferrer; Josep Ordi-Ros; Josefina Cortés-Hernández Background: Thalidomide has been used successfully in a variety of chronic refractory inflammatory dermatological conditions with underlying autoimmune or infectious pathogenesis. It was first used...

...% relapse. Oral corticosteroids had 100% response with 50% relapse. Thalidomide, cyclosporine or interferon-α had 100% response, but 100, 20 and 50% relapse, respectively. KD showed clinicopathological similarities with 27 published cases of cutaneous IgG4-RD. Conclusion: Surgery may be used in resectable...

...Tina P. Andersen; Karsten Fogh The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects. 77 medical records were retrospectively reviewed...

.... The symptoms lasted 12 years and were efficiently treated by thalidomide. A 17-year-old girl presented CLH which had begun at the age of 8 at the site of hepatitis B vaccination. The lesions progressively enlarged and disseminated far from the injection sites. There was no spontaneous remission. Cyclins...

...J. Sheskin; R. Gorodetzky; E. Loewinger; A. Weinreb The concentration of iron, copper and zinc in the skin of patients with prurigo nodularis was measured by diagnostic X-ray spectrometry before and after treatment with thalidomide. Before treatment, larger skin lesions were associated...

...F. Scolari; M. Harms; S. Gilardi The effect of thalidomide was investigated in 12 patients with chronic lupus erythematosus resistant to classical treatment (antimalarial drugs, topical steroids). 10 patients were improved and 2 were not sensitive to the treatment. The doses were 100 mg/day...

...M.F. Genvo; M. Faure; J. Thivolet Thalidomide alone (200–300 mg daily) or associated with colchicine (2–3 mg daily) was given orally to 25 patients with aphthosis: 8 patients with recurrent oral aphthae; 4 patients with recurrent mucocutaneous aphthosis, without visceral involvement, and 13...

...I. Bielsa; J. Teixidó; M. Ribera; C. Ferrándiz Cutaneous reactions to thalidomide therapy are reported infrequently. We report two new cases. Both patients suffered from chronic renal insufficiency and were on thalidomide therapy because of prurigo nodularis. The cutaneous reaction consisted...

...J.M. Bonnetblanc; C. Royer; C. Bedane Background: Thalidomide is used for the symptomatic treatment of recurrent aphthous stomatitis (RAS). Some authors reported remissions, but this was not evaluated. Objective: To evaluate the number of patients who could stop or reduce thalidomide treatment...

... nodularis Thalidomide Ultraviolet B ...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Thalidomide Headache Migraine Correspondence and Opinions Published online: October 2, 2008 Dermatology 2009;218:285...

... of thalidomide in patients with AIDS-related KS. Objective: To evaluate the efficacy of thalidomide in 3 patients with non-AIDS-related KS. Methods: Two patients with classic widespread cutaneous and 1 with iatrogenic cutaneous and visceral KS were treated with thalidomide (100 mg/day) for 12 months. Results...

...Lilia Ben M’barek; Laurence Fardet; Amel Mebazaa; Eric Thervet; Israel Biet; Delphine Kérob; Patrice Morel; Céleste Lebbe Background: Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies. Several studies have suggested its...

... associated with an IgG-λ paraprotein. Treatment with thalidomide was started and great improvement of the lesion was noted as shown by a quality of life questionnaire similar to those used in rheumatoid arthritis. TNF-α value was elevated in both cases during this treatment. Discussion: We hypothesize...

... of scleromyxedema is a benign plasma cell dyscrasia. Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects. We report a severe case of scleromyxedema who had marked improvement when treated with thalidomide. Scleromyxedema Thalidomide...

... strategies. Thalidomide (N-phtalimidoglutarimide), initially used as a tranquilizer, has recently been used in the management of several inflammatory skin diseases. We describe the case of a 38-year-old male with mucocutaneous LCH. A treatment course with 6 cycles of 2-chlorodeoxyadenosin (cladribine...

...Athanassios Kolivras; Josiane De Maubeuge; Josette André; Micheline Song We report a case of recurrent vulvar ulcerations developed on vegetations associated with Crohn’s disease. Lesions responded to low-dose thalidomide treatment. A biopsy revealed a neutrophilic infiltrate with rare giant cells...

...T. Nijsten; L. Meuleman; W. Schroyens; J. Lambert In the past few years, thalidomide is experiencing a revival in many different fields as a last therapeutic option, because of the potential severe adverse drug reactions (ADR) induced by this drug (teratogenicity, peripheral neuropathy and sedation...